During this podcast, we speak to Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis; Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer; and Lishan Aklog, CEO of Lucid Diagnostics, w developed a cell-collection method that aims to bring forward the stage at which esophageal cancer can be diagnosed.
The trio discuss the companies’ products and why they are transformative, as well as the upcoming regulatory and commercial hurdles...